Allogeneic hematopoietic stem cell transplantation (AHSCT) in Jehovah's Witness patients is a challenging procedure 1,2 because they do not accept transfusion of any blood products, as prohibited by their religious beliefs. Several supportive methods have been employed to limit the life-threatening anemia in these patients, like the use of recombinant human erythropoietin (rHuEpo) prior to conditioning chemotherapy in an attempt to raise the hemoglobin (Hgb) and hematocrit (HCT) levels 3 or the use of blood conservation methods to minimize blood loss. Both techniques have been used in autologous transplantation 4 but experience with allogeneic stem cell transplantation is very limited.
A 44-years-old Jehovah's Witness female patient was diagnosed with chronic phase, chronic myelogenous leukemia (CML) with t(9;22) in August 2002. She was initially treated with hydroxyurea then continued on imatinib mesylate 600 mg daily. The patient achieved hematologic but not cytogenetic remission. After 42 months she progressed to accelerated phase when she was found to have a new chromosomal abnormality, inv (13q) and was referred for AHSCT. At 3 weeks prior to conditioning chemotherapy, the patient was started on epoietin alfa 40 000 units once weekly. Subsequently, she received one dose of darbepoetin 200 mcg. Hgb and HCT values were 10.3 g/dl and 31.0%, respectively, at the beginning of erythropoietin therapy which rapidly normalized after the first two doses. In addition, methods previously used for 'bloodless' autologous stem cell transplantation 4 were used for the first time in an allogeneic transplant setting. These were: (1) pediatric tubes for blood draws, (2) decreased frequency (CBC, chemistry) to every other day, liver function tests twice weekly, PT/PTT once weekly, (3) closed system return of the waste blood after blood draws, (4) gastrointestinal prophylaxis with proton pump inhibitor, (5) folic acid and iron supplementation daily, vitamin K once weekly, (6) aminocaproic acid for platelet count below 30 000/ml. (7) oxygen support for Hgb o9 g/dl or symptomatic anemia was not required, and (8) oral contraceptives were not used because she had hysterectomy.
The patient was conditioned with fludarabine 40 mg/m 2 / day i.v. on days À9 to À6 (total dose 160 mg/kg), and busulfan 3.2 mg/kg/day i.v. on days À5 to À2 (total dose 12.8 mg/kg). GVHD prophylaxis included tacrolimus 0.03 mg/kg/day starting on day À2 and methotrexate 15 mg/m 2 on day þ 1 and then 10 mg/m 2 on day þ 3, þ 6, and þ 11. Peripheral blood stem cells were collected from her HLA-matched sibling, which were depleted of RBCs and plasma. The patient's graft contained 7.49 Â 10 6
CD34
þ cells/kg. At the time of transplant, the patient had splenomegaly (4 cm below LCM) and blood cell counts were: WBC count 3800/ml, Hgb 12.0 g/dl, HCT 35.8%, platelet count 139 000/ml. Interestingly, the Hgb and HCT remained normal throughout hospitalization and there was only moderate thrombocytopenia. Hgb never dropped below 12 g/dl and the platelets count never decreased to less than 20 000/ml throughout the time of neutropenia (Figure 1) . ANC recovered to 4500/ml on day þ 16. Among possible explanations for the lack of anemia and for only moderate thrombocytopenia throughout the transplant could be a host bone marrow not heavily treated with chemotherapy prior to transplant and the use of rHuEpo. Erythropoietin has been shown to increase platelet count in animal models 5 and in several clinical reports. 6, 7 The only complication of transplant was a right upper extremity superficial vein thrombosis on day þ 17 at the site of the PICC line, which was removed. No significant bleeding complications occurred except minor skin ecchymoses. Chimerism studies performed on the bone marrow obtained on day þ 30, þ 60 and þ 90 consistently showed more than 95% cells of donor origin. Both standard cytogenetics and FISH were negative on day þ 30 bone marrow sample after transplant. A pre-transplant Hgb level 411 g/dl should be considered the cutoff to start conditioning chemotherapy since it has been strongly associated with increased survival, as compared with patients with Hgb o10 g/dl in AHSCT patients. 8 The use of measures to perform 'bloodless' AHSCT could be exploited also in other patients. This would limit, for example, the risk of transmission of viral infections 9,10 associated with blood transfusions, and it could also be cost-effective. The need for blood transfusions is highest during the first 60 days post transplant. In a retrospective review of 519 patients receiving AHSCT, the mean PRBC utilization was 10.4 units per patient, about two-thirds being used during the first 60 days. 8 The cost of one unit of packed red blood cells transfused to a stem cell transplant patient is about $600 compared with about $500 per dose of erythropoietin and $900 per dose of darbepoetin. Based on previous experiences in autologous HSCT 3, 4 Platelet count nadir was 23 000/ml on post transplantation day 7 then quickly returned to normal.
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